11ÔÂ17-19ÈÕ£¬£¬ÄϹ¬NG28¼¯ÍÅʳÎï¿Æ¼¼Ñ§ÔºËβɽÌÊÚÂÊÁìÑо¿Éú¼ÓÈëÓɱ±¾©´óѧ»ØÁú¹ÛÒ½ÔºÖ÷ÀíµÄµÚ¶þ½ì¡°¾«ÉñÎÀÉúѧ¿Æ¿ªÕ¹ÓëÁ¢Ò족ÂÛ̳ôß±±¾©»ØÁú¹ÛÒ½ÔºÍâÑó»ªÈ˾«ÉñҽѧÁªÃ˵ڶþ´Î¾Û»á¡£±¾´Î´ó»áͬʱ¾ÙÐÐÁ˱±¾©ÐÄÀíΣ»£»£»úÑо¿Óë¸ÉÔ¤ÖÐÐijÉÁ¢15ÖÜÄê¡¢¡¢ÌìÏÂÎÀÉú×éÖ¯£¨WHO£©ÐÄÀíΣ»£»£»úÔ¤·ÀÑо¿ÓëÅàѵÏàÖúÖÐÐÄÊÚȨ10ÖÜÄêËêÄîÒÇʽ¡£À´×ÔÃÀ¹úÂíÀïÀ¼´óѧ¡¢¡¢°Ä´óÀûÑÇÎÔÁú¸Ú´óѧ¡¢¡¢ÃÀ¹úÈ«ÇòÁÙ´²Óëת»¯Ñо¿Ëù¡¢¡¢ÃÀ¹úÇÇÖÎÑÇÖÝÁ¢´óѧ¡¢¡¢ÃÀ¹úÆ¥×ȱ¤´óѧµÈ20ÓàλÍâÑó»ªÈ˾«Éñҽѧ×ÅÃûר¼Ò¡¢¡¢10ÓàÃûº£ÄÚ¾«ÉñҽѧÑо¿ÁìÓòµÄר¼Ò¼°À´×Ôº£ÄÚ80Óà¼ÒÏàÖúµ¥Î»µÄ¼Î±öÅóÙ¹²¼Æ420ÓàÈ˼ÓÈëÁË´Ë´ÎÂÛ̳¡£Öйú¼²²¡Ô¤·ÀÓë¿ØÖÆÖÐÐĸ±Ö÷ÈÎÁºÏþ·å¡¢¡¢±±¾©ÊÐÒ½ÔºÖÎÀí¾Ö¸±¾Ö³¤ÅËËÕÑå³öϯÁ˾ۻᡣ
»áÉÏ£¬£¬º£ÄÚÍâר¼Ò¾ÍҽѧÑо¿Éè¼Æ¡¢¡¢¾«ÉñÕϰµÄÓ°Ïñѧ¡¢¡¢¾«ÉñÕϰµÄÉúÎï±ê¼Ç¡¢¡¢³£¼û¾«ÉñÕϰµÄÁÙ´²Ñо¿¡¢¡¢ÐÄÀíÖÎÁÆÑо¿Ï£Íû¼°×ÔɱδËìÐÐΪµÄÌØÕ÷¡¢¡¢ÐÄÀíΣ»£»£»ú¸ÉÔ¤ÊÖÒÕ¡¢¡¢×Ô±ÕÖ¢¶ùͯÔçÆÚÆÀ¹À¡¢¡¢Õï¶Ï¼°¶àѧ¿Æ½éÈë¡¢¡¢ÉçÇø¸´ÔªÐÂÏ£Íû¡¢¡¢ÎÂÄá¿ÆÌØÑ§Åɼ°À¿µ¾«ÉñÆÊÎöѧÅÉÔÚÖйúµÄ¿ªÕ¹µÈ¶à¸öÈÈÃÅÌâÕö¿ªÁËÉîÈëµÄÌÖÂÛ¡£ÄϹ¬NG28¼¯ÍÅËβɽÌÊÚ×÷ÎªÌØÑûר¼Ò£¬£¬Á¬ÏµÍŶÓÏÖÔÚÔÚÒÖÓôÖ¢ºÍº£Ñó×ÔÈ»²úÆ··½ÃæµÄÑо¿Ð§¹û×÷ÁËÌâΪ¡°Endogenic n-3 fatty acids attenuated depression-like behabior imbalance between microglia M1 and M2 phenotypes and dysfunction of neurotrophins induced by LPS administration¡±µÄ±¨¸æ£¬£¬ËνÌÊÚÖ¸³öÑ×Ö¢ÊÇÓÕ·¢´óÄÔÐàÂõ¡¢¡¢ÒÖÓôÖ¢ºÍ°¢¶û´Äº£Ä¬²¡µÈÉñ¾ºÍ¾«Éñ¼²²¡µÄÖ÷ÒªÒòËØÖ®Ò»£¬£¬¶ø´ÓÓãϺ¡¢¡¢º£ÔåµÈº£ÑóÉúÎïÌáÈ¡³öÈËÌ屨ÐèµÄ²»±¥ºÍÖ¬·¾Ëá¾ßÓп¹Ñ׺ͱ£»£»£»¤Éñ¾µÄ×÷Ó㬣¬¿É³ÉΪ¸ÄÉÆ´óÄÔÓ°Ï󡢡¢·ÀÖÎÒÖÓôµÈÉñ¾¾«Éñ¼²²¡Ò©Î↑·¢µÄÒ»¸öÐÂ˼Ð÷¡£»£»£¾Û»áʱ´ú£¬£¬ÄϹ¬NG28¼¯ÍÅʦÉúÓë¹ú¼ÊÙÉÐÐר¼Ò¾Í¾«ÉñҽѧÑо¿ºÍÐÄÀíΣ»£»£»ú¸ÉÔ¤Ñо¿ÁìÓò¾ÙÐÐÁËÆÕ±éºÍÉîÈëµØ½»Á÷¡£
ͨ¹ý¼ÓÈë´Ë´ÎѧÊõÂÛ̳£¬£¬Ôö½øÁËÄϹ¬NG28¼¯ÍÅʦÉúÓ뺣ÄÚÍâÙÉÐÐר¼ÒѧÕßµÄѧÊõ½»Á÷£¬£¬¹ØÓÚÄϹ¬NG28¼¯ÍÅÔÚº£ÑóÒ©ÎïÁìÓòµÄ¿ªÕ¹ºÍÌáÉýÄϹ¬NG28¼¯ÍÅÔÚº£ÄÚÍâµÄÓ°ÏìÁ¦¾ßÓÐÖ÷Òª×÷Óá£



£¨ÐÂÎÅÖ÷±à£º£º³ÂäÆÌí£©